Pancreatic Cancer Research

ResearcherMarche Polytechnic UniversityActive in the last 2 years

Giulio Belfiori

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7334-2878; OpenAlex author ID A5062765910. Sources: OpenAlex.

Their work

Papers
45 (first author 8, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
116
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 2 papers · 2021: 6 papers · 2022: none · 2023: 9 papers · 2024: 9 papers · 2025: 5 papers · 2026: 9 papers

Papers 45

  1. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
  2. Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. Co-author DOI 10.1007/s00423-026-04291-0↗
  3. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. First author DOI 10.1007/s13304-026-02813-5↗
  4. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the … Co-author DOI 10.1016/s0140-6736(25)01685-x↗
  5. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  6. Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/sla.0000000000007214↗
  7. Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. First author DOI 10.1245/s10434-026-19218-8↗
  8. ASO Visual Abstract: Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. First author DOI 10.1245/s10434-026-19370-1↗
  9. ASO Author Reflections: Early Disease-Related Mortality After Neoadjuvant Therapy and Radical Resection for Pancreatic Ductal Adenocarcinoma-The Biological Bur… First author DOI 10.1245/s10434-026-19400-y↗
  10. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  11. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  12. Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological a… Co-author DOI 10.1093/bjsopen/zraf033↗
  13. Reappraising the Role of Intraoperative Neck Margin Revision in Postneoadjuvant Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Multi-institution… Co-author DOI 10.1097/sla.0000000000006322↗
  14. Prognostic Validation of Perineural Invasion Severity Score in Pancreatic Cancer: A Prospective Study. Co-author DOI 10.1097/sla.0000000000006920↗
  15. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  16. Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2024.2485↗
  17. Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ctro.2024.100778↗
  18. Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy. First author DOI 10.1016/j.dld.2023.07.006↗
  19. Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence. Co-author DOI 10.1016/j.surg.2024.07.026↗
  20. Margin clearance greater than 1 mm in nodal-positive pancreatic adenocarcinoma patients: multicentre retrospective analysis. Co-author DOI 10.1093/bjsopen/zrae076↗
  21. Cure Probabilities After Resection of Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Analysis of 2554 Patients. Co-author DOI 10.1097/sla.0000000000006166↗
  22. Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a "Biological R2 Definition". Co-author DOI 10.1245/s10434-024-15105-2↗
  23. ASO Author Reflections: Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: The Challenge of Minimal Residual Disease. Co-author DOI 10.1245/s10434-024-15175-2↗
  24. Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. Co-author DOI 10.1002/deo2.152↗
  25. Quantification of perineural invasion in pancreatic ductal adenocarcinoma: proposal of a severity score system. Co-author DOI 10.1007/s00428-023-03574-x↗
  26. Surgical Planning for "Borderline Resectable" and "Locally Advanced" Pancreatic Cancer During Open Pancreatic Resection. Co-author DOI 10.1007/s11605-023-05848-w↗
  27. The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.dld.2023.04.015↗
  28. Pro-tumor Tfh2 cells induce detrimental IgG4 production and PGE2-dependent IgE inhibition in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2023.104819↗
  29. Pancreatectomy with venous vascular resection for pancreatic cancer: Impact of types of vein resection on timing and pattern of recurrence. First author DOI 10.1016/j.ejso.2023.03.229↗
  30. Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy. Co-author DOI 10.1093/bjs/znad146↗
  31. CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal… Co-author DOI 10.1245/s10434-022-12622-w↗
  32. Role of pancreatic ductal adenocarcinoma risk factors in intraductal papillary mucinous neoplasm progression. Co-author DOI 10.3389/fonc.2023.1172606↗
  33. Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. Co-author DOI 10.1007/s00280-020-04190-1↗
  34. Recurrence after surgical resection of pancreatic cancer: the importance of postoperative complications beyond tumor biology. First author DOI 10.1016/j.hpb.2021.04.004↗
  35. The Oncologic Impact of Pancreatic Fistula After Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma of the Body and the Tail: A Multicenter Retrospecti… Co-author DOI 10.1245/s10434-020-09310-y↗
  36. Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival. Co-author DOI 10.1245/s10434-021-10401-7↗
  37. ASO Author Reflections: Long-Term Survivors after Upfront Resection for Pancreatic Cancer: Do They Really Exist? Co-author DOI 10.1245/s10434-021-10402-6↗
  38. Prediction of Early Distant Recurrence in Upfront Resectable Pancreatic Adenocarcinoma: A Multidisciplinary, Machine Learning-Based Approach. Co-author DOI 10.3390/cancers13194938↗
  39. Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic can… Co-author DOI 10.1016/j.ejso.2020.02.013↗
  40. The Role of Hyponatraemia Before Surgery in Patients With Radical Resected Pancreatic Cancer. Co-author DOI 10.1177/1179554920936605↗
  41. Prognostic impact of Ki-67 proliferative index in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/bjs5.50175↗
  42. Postoperative Outcomes and Functional Recovery After Preoperative Combination Chemotherapy for Pancreatic Cancer: A Propensity Score-Matched Study. Co-author DOI 10.3389/fonc.2019.01299↗
  43. Nerves and Pancreatic Cancer: New Insights into a Dangerous Relationship. Co-author DOI 10.3390/cancers11070893↗
  44. SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer. Co-author DOI 10.1016/j.dld.2017.09.122↗
  45. A preoperative score to predict early death after pancreatic cancer resection. Co-author DOI 10.1016/j.dld.2017.06.012↗

Closest collaborators

The 25 strongest of 116 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Massimo Falconi · 38 shared papers, 2017–2026 · strength 6.63
  2. Stefano Crippa · 36 shared papers, 2017–2026 · strength 6.23
  3. Domenico Tamburrino · 19 shared papers, 2019–2026 · strength 3.37
  4. Stefano Partelli · 19 shared papers, 2018–2026 · strength 3.16
  5. Michele Reni · 17 shared papers, 2017–2026 · strength 2.88
  6. Giulia Gasparini · 16 shared papers, 2019–2026 · strength 2.71
  7. Marco Schiavo Lena · 14 shared papers, 2019–2026 · strength 2.54
  8. Federico De Stefano · 10 shared papers, 2023–2026 · strength 2.28
  9. Giuseppe Malleo · 9 shared papers, 2023–2026 · strength 1.75
  10. Diego Palumbo · 9 shared papers, 2021–2026 · strength 1.71
  11. Claudio Doglioni · 11 shared papers, 2017–2025 · strength 1.54
  12. Gabriella Lionetto · 8 shared papers, 2023–2026 · strength 1.54
  13. Roberto Salvia · 8 shared papers, 2023–2026 · strength 1.54
  14. Nicolò Pecorelli · 8 shared papers, 2019–2026 · strength 1.52
  15. Francesco DE COBELLI · 7 shared papers, 2021–2026 · strength 1.31
  16. Marina Macchini · 6 shared papers, 2021–2026 · strength 1.05
  17. Giulia Orsi · 6 shared papers, 2021–2026 · strength 1.05
  18. Fabio Casciani · 5 shared papers, 2024–2026 · strength 1.01
  19. Gianpaolo Balzano · 7 shared papers, 2017–2026 · strength 0.99
  20. Claudio Luchini · 5 shared papers, 2023–2026 · strength 0.95
  21. Paolo Riccardo Camisa · 4 shared papers, 2024–2026 · strength 0.85
  22. Carlos Fernández-del Castillo · 4 shared papers, 2023–2026 · strength 0.77
  23. Gabriele Capurso · 4 shared papers, 2023–2026 · strength 0.67
  24. Paolo Giorgio Arcidiacono · 4 shared papers, 2023–2026 · strength 0.67
  25. Motaz Qadan · 3 shared papers, 2025–2026 · strength 0.62

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.